AGBT had lots of presentations on both clinical and single-cell work last February and on Wednesday, February 12th Aviv Regev, of the Broad Institute described her groups experience with the Fluidigm C1 system, and their early work in understanding cell-to-cell communication in the immune system. The results were published in Nature a couple of days ago. A more exciting story for me scientifically was published by Aviv Regev and Bradley Bernstein in Science awhere they describe the use of single-cell sequencing to understand tumour heterogeneity.
The big headlines for me were that just 1M RNA-seq reads were enough to get high-quality gene expression estimates, and that single cells are great: but we’re going to need lots of them to delve deeply into biological systems. Both papers showed a massive loss of data at QC stages, around 1/3rd of cells were lost and only 30% of reads mapped to the transcriptome. Hopefuly both of these are things we can improve in the next few years to make single-cell mRNA-seq even more powerful.




